Guidance and quality standards Awaiting development

Showing 21 to 30 of 291

Guidance and quality standards awaiting development
Title	Type
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]	Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]	Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]	Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration ID6401	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769	Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance